<div id="readability-page-1"><div><ul> <li>Recursion Pharmaceuticals recently announced significant advancements in its AI-driven drug discovery platform, highlighted by its merger with Exscientia and regulatory clearances for new oncology assets.</li> <li>Management projects reduced cash burn and funding through late 2027, even as insider selling and mixed analyst sentiment persist amid excitement over upcoming late-stage trial readouts.</li> <li>We will examine how Recursion's expanded AI capabilities and pipeline updates could impact its investment narrative going forward.</li> </ul><p>Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.</p><h2>Recursion Pharmaceuticals Investment Narrative Recap</h2><p> For investors in Recursion Pharmaceuticals, belief in the power of AI to transform drug discovery, and the possibility that proprietary technology and partnerships can deliver breakthrough therapies, remains key. The recent excitement around the Exscientia merger and AI platform advances does increase buzz, but the most important near-term catalyst is still upcoming late-stage trial data; the biggest risk remains Recursion's unprofitable business with a finite cash runway. While the merger expands capabilities, it does not materially change these short-term stakes. </p> <p> Among the latest announcements, management's revised projections for reduced cash burn and funding coverage through late 2027 stand out. Although this addresses runway concerns and provides some financial flexibility, the business continues to report significant losses, making pipeline progress and successful late-stage trials all the more critical to any shift in sentiment. </p> <p> Yet despite recent advances, investors should also keep in mind the uncertainties that stem from Recursion’s heavy reliance on partnership revenue and the consequences if those collaborations... </p> <p>Read the full narrative on Recursion Pharmaceuticals (it's free!)</p><p>Recursion Pharmaceuticals' outlook anticipates $220.9 million in revenue and $35.5 million in earnings by 2028. This scenario assumes an annual revenue growth rate of 50.7% and an earnings increase of $684.6 million from current earnings of -$649.1 million.</p><p>Uncover how Recursion Pharmaceuticals' forecasts yield a $6.47 fair value, a 7% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/34123d23-8c26-4477-813f-766698a0ea92/chart/community-fair-value?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/34123d23-8c26-4477-813f-766698a0ea92/chart/community-fair-value"/><figcaption>RXRX Community Fair Values as at Oct 2025</figcaption></figure> <p> Five fair value estimates from the Simply Wall St Community range from US$1.92 to US$10, revealing wide variance in expectations. This disparity speaks to the ongoing tension between optimism over AI-driven R&amp;D acceleration and concerns about financial sustainability and clinical milestones. </p><p>Explore 5 other fair value estimates on Recursion Pharmaceuticals - why the stock might be worth as much as 66% more than the current price!</p><h2>Build Your Own Recursion Pharmaceuticals Narrative</h2><p>Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.</li><li>Our free Recursion Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.</li></ul><h2>Ready To Venture Into Other Investment Styles?</h2><p>The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:</p><ul><li>This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.</li><li>These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li><li>Uncover the next big thing with financially sound penny stocks that balance risk and reward.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p></div></div>

RXRX

<p>Recursion Pharmaceuticals (RXRX) has seen a 9.6% decline following its merger with Exscientia and updates on its AI-driven drug discovery platform. Despite management's projections for reduced cash burn and funding through late 2027, concerns remain over insider selling and mixed analyst sentiment. The company anticipates significant revenue growth by 2028, but its reliance on partnership revenue and ongoing losses pose risks. Fair value estimates for RXRX vary widely, reflecting uncertainty in its financial sustainability and clinical milestones.</p>

Why Recursion Pharmaceuticals (RXRX) Is Down 9.6% After AI Merger With Exscientia and Pipeline Update